Alzai Health (FRA:H2F) 3-1 Month Momentum %: N/A% (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H2F Alzai Health Corp FRA:H2F
9 GF Score
Price €0.17
! 1 Warning Sign
View Full Analysis

What is Alzai Health 3-1 Month Momentum %?

Alzai Health FRA:H2F -1.62% 9 3-1 Month Momentum % is N/A% as of Aug. 08, 2026. GuruFocus rates FRA:H2F with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 1,387 Biotechnology companies, Alzai Health ranks worse than 72097.98% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-08), Alzai Health's 3-1 Month Momentum % is N/A%.

The industry rank for Alzai Health's 3-1 Month Momentum % or its related term are showing as below:

FRA:H2F's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -6.98
* Ranked among companies with meaningful 3-1 Month Momentum % only.

Alzai Health  (FRA:H2F) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Alzai Health 3-1 Month Momentum % Related Terms

FRA:H2F
9GF Score
Alzai Health Corp FRA:H2F
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzai Health  (FRA:H2F) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
Alzai Health (FRA:H2F) has a 3-1 Month Momentum % of N/A% as of Aug. 08, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Alzai Health and its competitors. According to the industry distribution chart, Alzai Health ranks #999999 out of 1387 companies in the Biotechnology industry.
Is Alzai Health's 3-1 Month Momentum % too high?
Alzai Health's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Alzai Health ranks #999999 out of 1387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzai Health has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Alzai Health's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alzai Health ranks #999999 out of 1387 companies for 3-1 Month Momentum %. This places Alzai Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Alzai Health and its competitors. Alzai Health's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzai Health stock overvalued right now?
Alzai Health (FRA:H2F) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Alzai Health's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Alzai Health (FRA:H2F), the current 3-1 Month Momentum % is N/A% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzai Health Business Description

Other Exchanges ALZI:Canada
Address 22 Adelaide Street West, Suite 3400, Toronto, ON, CAN, M5H 4E3
Alzai Health Corp is a healthcare company focused on comprehensive health solutions. It is an AI-driven Alzheimer's disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes. The company uses low-cost, non-invasive, pre-existing biomarker data present in nearly all Electronic Medical Records of the relevant age demographic. It aims to address the unmet need in Alzheimer's screening, enabling early detection and mitigation driving to diagnosis, therapy or prevention.
9GF Score

Get the complete analysis for FRA:H2F

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price